DOCSLIB.ORG

HIV/AIDS Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HIV/AIDS Guidelines Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America How to Cite the Adult and Adolescent Opportunistic Infection Guidelines: Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed (insert date) [include page numbers, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is Access AIDSinfo available on the AIDSinfo website (http://aidsinfo.nih.gov). mobile site What’s New in the Guidelines Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format that can be easily updated as relevant changes in prevention and treatment recommendations occur. The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information. All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows: May 26, 2020 1. Candidiasis (Mucocutaneous): The Panel updated the text, treatment, pregnancy considerations, references, and treatment table and made the following key changes: • Added important new information on spontaneous abortion in pregnant women after any exposure to fluconazole (low—even single-dose—or high exposure). • Added a brief discussion on the gentian violet topical application randomized clinical trial for oral candidiasis and updated the treatment table. • Added a statement indicating that azole resistance can be seen in vulvovaginal candidiasis caused by non-C. albicans species. • Added details for the use of boric acid in azole-refractory C. glabrata vaginitis in the treatment table. 2. Herpes Simplex Virus: The Panel updated references throughout the section and improved the readability of the text. In addition, the Panel made the following key changes: • Updated information about the seroprevalence of HSV-1 and HSV-2 in the United States.. • Addressed HSV-1 as a cause of genital herpes. • Provided additional information about the interpretation of type-specific HSV serologic assays. • Updated information about prevention methods for HSV-2 infection. • Updated information about treatment of acyclovir-resistant HSV infection. February 11, 2020 1. Table 8. Summary of Pre-Clinical and Human Data on, and Indications for, Opportunistic Infection Drugs During Pregnancy: The Panel updated this table to include the following key changes: • Information on several new drug combinations for hepatitis C treatment have been added, including dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ombitasvir/ paritaprevir/ritonavir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir. Data on the use of these new drugs in pregnancy are limited but they can be used if the benefit is felt to outweigh the potential risks. However, ribavirin is contraindicated during pregnancy so regimens including ribavirin should not be used in pregnant women. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV i • Information on isavuconazole, a new oral antifungal, has been added. Use in pregnancy is not recommended. • Information on rifapentine has been added. Given malformations and fetal loss noted in animal studies, use of alternate drugs for tuberculosis treatment and prophylaxis in pregnancy are recommended. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV ii Table of Contents What’s New in the Guidelines ..........................................................................................................................i Introduction ..................................................................................................................................................A-1 Bacterial Enteric Infections ........................................................................................................................ B-1 Bartonellosis ................................................................................................................................................. C-1 Candidiasis (Mucocutaneous) .....................................................................................................................D-1 Chagas Disease ............................................................................................................................................. E-1 Coccidioidomycosis .......................................................................................................................................F-1 Community-Acquired Pneumonia .............................................................................................................G-1 Cryptococcosis ..............................................................................................................................................H-1 Cryptosporidiosis .......................................................................................................................................... I-1 Cystoisosporiasis ........................................................................................................................................... J-1 Cytomegalovirus Disease .............................................................................................................................K-1 Hepatitis B Virus Infection ......................................................................................................................... L-1 Hepatitis C Virus Infection ........................................................................................................................ M-1 Herpes Simplex Virus Disease .....................................................................................................................N-1 Histoplasmosis ..............................................................................................................................................O-1 Human Herpesvirus-8 Disease .....................................................................................................................P-1 Human Papillomavirus Disease ..................................................................................................................Q-1 Leishmaniasis ............................................................................................................................................... R-1 Malaria ...........................................................................................................................................................S-1 Microsporidiosis ............................................................................................................................................T-1 Mycobacterium avium Complex Disease .....................................................................................................U-1 Mycobacterium tuberculosis Infection and Disease ................................................................................... V-1 Pneumocystis Pneumonia............................................................................................................................ W-1 Progressive Multifocal Leukoencephalopathy/JC Virus Infection .........................................................X-1 Syphilis .......................................................................................................................................................... Y-1 Talaromycosis (Penicilliosis) ....................................................................................................................... Z-1 Toxoplasma gondii Encephalitis ...............................................................................................................AA-1 Varicella-Zoster Virus Diseases ............................................................................................................... BB-1 Tables Table 1. Prophylaxis to Prevent First Episode of Opportunistic Disease ..................................... CC-1 Table 2. Treatment of AIDS-Associated Opportunistic Infections (Includes Recommendations Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV iv for Acute Treatment and Chronic Suppressive/Maintenance Therapy) ......................................... CC-7 Table 3. Recommended Doses of First-Line Drugs for Treatment of Tuberculosis
Load more

Recommended publications
  • Estimated Burden of Fungal Infections in Oman
    Journal of Fungi Article Estimated Burden of Fungal Infections in Oman Abdullah M. S. Al-Hatmi 1,2,3,* , Mohammed A. Al-Shuhoumi 4 and David W. Denning 5 1 Department of microbiology, Natural & Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman 2 Department of microbiology, Centre of Expertise in Mycology Radboudumc/CWZ, 6500 Nijmegen, The Netherlands 3 Foundation of Atlas of Clinical Fungi, 1214GP Hilversum, The Netherlands 4 Ibri Hospital, Ministry of Health, Ibri 115, Oman; [email protected] 5 Manchester Fungal Infection Group, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, UK; [email protected] * Correspondence: [email protected]; Tel.: +968-25446328; Fax: +968-25446612 Abstract: For many years, fungi have emerged as significant and frequent opportunistic pathogens and nosocomial infections in many different populations at risk. Fungal infections include disease that varies from superficial to disseminated infections which are often fatal. No fungal disease is reportable in Oman. Many cases are admitted with underlying pathology, and fungal infection is often not documented. The burden of fungal infections in Oman is still unknown. Using disease frequencies from heterogeneous and robust data sources, we provide an estimation of the incidence and prevalence of Oman’s fungal diseases. An estimated 79,520 people in Oman are affected by a serious fungal infection each year, 1.7% of the population, not including fungal skin infections, chronic fungal rhinosinusitis or otitis externa. These figures are dominated by vaginal candidiasis, followed by allergic respiratory disease (fungal asthma). An estimated 244 patients develop invasive aspergillosis and at least 230 candidemia annually (5.4 and 5.0 per 100,000).
    [Show full text]
  • 16. Questions and Answers
    16. Questions and Answers 1. Which of the following is not associated with esophageal webs? A. Plummer-Vinson syndrome B. Epidermolysis bullosa C. Lupus D. Psoriasis E. Stevens-Johnson syndrome 2. An 11 year old boy complains that occasionally a bite of hotdog “gives mild pressing pain in his chest” and that “it takes a while before he can take another bite.” If it happens again, he discards the hotdog but sometimes he can finish it. The most helpful diagnostic information would come from A. Family history of Schatzki rings B. Eosinophil counts C. UGI D. Time-phased MRI E. Technetium 99 salivagram 3. 12 year old boy previously healthy with one-month history of difficulty swallowing both solid and liquids. He sometimes complains food is getting stuck in his retrosternal area after swallowing. His weight decreased approximately 5% from last year. He denies vomiting, choking, gagging, drooling, pain during swallowing or retrosternal pain. His physical examination is normal. What would be the appropriate next investigation to perform in this patient? A. Upper Endoscopy B. Upper GI contrast study C. Esophageal manometry D. Modified Barium Swallow (MBS) E. Direct laryngoscopy 4. A 12 year old male presents to the ER after a recent episode of emesis. The parents are concerned because undigested food 3 days old was in his vomit. He admits to a sensation of food and liquids “sticking” in his chest for the past 4 months, as he points to the upper middle chest. Parents relate a 10 lb (4.5 Kg) weight loss over the past 3 months.
    [Show full text]
  • Aicuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
    AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults Wuppertal, August 01, 2017 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults. Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner. Oral pritelivir, a small molecule helicase-primase inhibitor with a novel mode of action, is currently in a clinical phase 2 study, called PRIOH-1, in the U.S. to evaluate the product candidate’s efficacy and safety compared to i.v. foscarnet, a virostatic agent which is used mainly for the treatment of herpes viruses resistant to other antiviral drugs. In a prior phase 2 study, oral pritelivir showed to significantly improve the suppression of viral shedding compared to the current standard of care for genital HSV-2 infections, the nucleoside analog valacyclovir. The results of this study were published in the Journal of the American Medical Association (JAMA) earlier this year. “The decision by the FDA to grant fast track designation to oral pritelivir underscores that our product might fill the major need for innovative, more efficacious therapies for immunocompromised patients with HSV infections that have become resistant to standard treatments,” said Dr.
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • Candida Ball in the Esophagus
    Case Report Adv Res Gastroentero Hepatol Volume 6 Issue 1 - June 2017 DOI: 10.19080/ARGH.2017.06.555677 Copyright © All rights are reserved by Mohammad Al-Shoha Case Report: Candida Ball in the Esophagus Mohammad Al-Shoha MD1*, Nayana George MD1 and Benjamin Tharian MD1,2 1Department of Internal Medicine, University of Arkansas for Medical Sciences, USA 2Department of Medicine, Division of Gastroenterology and Hepatology, USA Submission: February 10, 2017; Published: June 16, 2017 *Corresponding author: Mohammad Al-Shoha, Department of Internal Medicine, University of Arkansas for Medical Sciences, Internal Medicine, 4301 W. Markham Street, Slo t#634, Little Rock, AR 72205, USA, Tel: , Email: [email protected] Abstract Candida albicans is the most common well known cause of infectious esophagitis. Although most patients with Candida esophagitis are immunocompromised, about 25% have scleroderma, achalasia, or other causes of esophageal dysmotility that would allow the fungi to overgrow but it has been reported in the literature that it can manifest as an esophageal mass. We are reporting a case of recurrent esophageal candidiasis manifestingand colonize on the the esophagus, Esophagogastroduodenoscopy with subsequent esophagitis (EGD) as [1,2]. an obstructing Esophageal mass. candidiasis usually manifests as white mucosal plaque-like lesions Case report showed normal complete blood count, acute renal injury with A 70-year old African American male patient who presented creatinine 11.5mg/dL, sodium 127, potassium 3.9, normal with complaints of gradually worsening dysphagia for both TSH and negative HIV testing. Repeat EGD revealed a mass at solids and liquids with an EGD revealing a nearly obstructing 25cm from incisors (image A,B) with a biopsy revealing active mass in the esophagus 25cm from incisors occupying 75-99% of esophagitis with intraepithelial fungi consistent with Candida the circumference of the esophagus with the inability to traverse with no dysplasia and malignancy.
    [Show full text]
  • PRIOR AUTHORIZATION CRITERIA BRAND NAME (Generic) SPORANOX ORAL CAPSULES (Itraconazole)
    PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3
    [Show full text]
  • Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary?
    Gut and Liver, Vol. 3, No. 1, March 2009, pp. 31-34 original article Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary? Min Kyu Jung, Seong Woo Jeon, Chang Min Cho, Won Young Tak, Young Oh Kweon, Sung Kook Kim, and Yong Hwan Choi Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea Background/Aims: The inadequacy of information on ing; antimycotic therapy was advocated in such cases. By the treatment of gastric candidiasis with antifungal contrast, Minoli et al.3 and Gotlieb-Jensen et al.4 consid- agents promoted us to evaluate patients with fungal ered it an epiphenomenon without any significance. infections who had gastric ulcers and assess the However, because the issue remains unresolved we retro- need for proton-pump inhibitors or antifungal agents. spectively reviewed fungal infections in patients with gas- Methods: Sixteen patients were included in the study. tric ulcers to determine the need for proton pump in- The criterion for the diagnosis of candidiasis was find- hibitor and/or antifungal agents. ing yeast and hyphae in the tissue or an ulcer on histological sections of biopsy samples. Surface fungi were not considered infections. Results: In all cases MATERIALS AND METHODS with benign ulcers, follow-up endoscopy performed 6 weeks after proton-pump-inhibitor treatment revealed We reviewed the pathology specimens and medical re- that the ulcer had improved without antifungal medi- cords of patients with gastroduodenal ulcers diagnosed by cation. However, in patients with malignant ulcers, upper gastrointestinal endoscopy at Kyungpook National surgical resection was necessary for a definitive cure.
    [Show full text]
  • ACCP Toolkit the 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit
    ACCP Toolkit The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit 2016 Educational Afairs Committee, American College of Clinical Pharmacy Terry L. Schwinghammer (Chair), Andrew J. Crannage (Vice Chair), Eric G. Boyce, Bridget Bradley, Alyssa Christensen, Henry M. Dunnenberger, Michelle Fravel, Holly Gurgle, Drayton A. Hammond, Jennifer Kwon, Douglas Slain, and Kurt A. Wargo. Approved by the American College of Clinical Pharmacy Board of Regents on July 18, 2016. The purpose of the 2009 and 2016 ACCP Pharmacother- ORGAN SYSTEMS AND DISEASE STATE TOPICS apy Didactic Curriculum Toolkits is to provide guid- ance to schools and colleges of pharmacy in developing, Cardiovascular Disorders maintaining, and modifying their curricula.1,2 The 2016 1 Acute coronary syndromes (STEMI, NSTEMI, unstable ACCP Educational Affairs Committee reviewed recent angina) medical literature and other documents to identify dis- 1 Atherosclerotic cardiovascular disease, primary ease states that are responsive to drug therapy. Disease prevention frequency, socioeconomic burden to society, and impact 1 Atherosclerotic cardiovascular disease, secondary of pharmacist involvement in medication therapy were prevention considered in determining which topics to include in the updated pharmacotherapy toolkit. This updated toolkit 1 Arrhythmias, atrial (e.g., atrial fbrillation) is intended to provide valuable guidance to schools and 1 Basic life support (BLS) colleges of pharmacy as they develop, maintain, and 1 Dyslipidemia modify their curricula to keep pace with major scientific 1 Heart failure, chronic advances and practice changes. 1 Hypertension In the 2016 toolkit, diseases and content topics are 1 Ischemic heart disease, stable organized by organ system, when feasible, and grouped 1 Venous thromboembolism into tiers defined by practice competency.
    [Show full text]
  • AIDS-Related Mycoses in the Paediatric Population
    Current Fungal Infection Reports (2019) 13:221–228 https://doi.org/10.1007/s12281-019-00352-8 PEDIATRIC FUNGAL INFECTIONS (D CORZO-LEON, SECTION EDITOR) AIDS-Related Mycoses in the Paediatric Population B. E. Ekeng1 & O. O. Olusoga2 & R. O. Oladele3 Published online: 16 November 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Fungal infections account for significant morbidity and mortality in HIV-infected children particularly in developing countries where there is lack of skilled personnel and infrastructure to make the appropriate diagnosis. This is further compounded by poor availability and accessibility of the antifungals needed to treat these infections. The purpose of this review is to highlight the paucity of data on AIDS-related mycoses in the paediatric age group and make appropriate recommendations to address challenges associated with mycoses in this population. Recent Findings These infections are categorised in two broad groups in this population: mucocutaneous, which commonly affects nutrition and adherence to therapy and invasive fungal infections which are life-threatening. A literature search revealed a total of 29 published literatures across all AIDS-related mycoses in the paediatric population. Summary Research to determine the true burden of the problem and greater funding with implementation of a package of care that will result in substantial reductions in morbidity and mortality in relation to AIDS-related mycoses in children are needed. It is imperative that the programmatic optimal package of care for children with advanced HIV disease is designed and implemented. Keywords Mycoses . Paediatric . Advanced HIV disease . HIV/AIDS . LMICs Introduction defined as CD4+ of < 200 cells/mm3 or stage 3/4 disease (WHO staging) in children over 5 years of age, while any Advanced HIV disease (AHD) is one of the most current HIV-infected child less than 5 years is regarded as AHD [2••].
    [Show full text]
  • Predictors of Esophageal Candidiasis Among Patients Attending Endoscopy Unit in a Tertiary Hospital, Tanzania: a Retrospective Cross-Sectional Study
    Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study Martha F Mushi1, Nathaniel Ngeta2, Mariam M Mirambo1, Stephen E Mshana1 1. Microbiology and Immunology Department; Weill Bugando School of Medicine, P.O. Box 1464, Mwanza, Tanzania. 2. Department of Internal Medicine Weill Bugando School of Medicine. P.O. Box 1464 Mwanza, Tanzania. MFM: [email protected] NN: [email protected] MMM: [email protected] SEM: [email protected] Abstract Background: Esophageal candidiasis is a common disease among patients with impaired cell mediated immunity. In the current study, we report esophageal candidiasis among patients with various co-morbidities attending the endoscopic unit at the Bugan- do Medical Centre. Methods: This retrospective study was conducted from June to September 2015. All data of the patients who attended the endoscopic unit between 2009 and 2014 were retrieved and analyzed. Results: A total of 622 patients who underwent oesophagogastroduodenoscopy were analyzed. A slight majority 334/622(53.7%) of patients were female. Out of 622 patients; 35(5.6%) had esophageal candidiasis. Decrease in age (OR 1.1, 95%CI; 1.0-1.1), female sex (OR 3.8, 95%CI; 1.1-13.1), drinking alcohol (OR 17.1, 95%CI; 4.9-58.9), smoking (OR 8.3, 95%CI; 1.7-41.0), anti- biotic use (OR 5.7, 95%CI; 2.0-16.4), positive HIV status (OR 10.3, 95%CI; 4.6-6.0) and presence of peptic ulcer disease (OR 13.2, 95%CI; 3.5-49.0) independently predicted esophageal candidiasis.
    [Show full text]
  • A Geosentinel Analysis, 1997–2017
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Travel Manuscript Author Med. Author manuscript; Manuscript Author available in PMC 2019 July 15. Published in final edited form as: J Travel Med. 2018 August 01; 25(1): . doi:10.1093/jtm/tay055. Epidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997–2017 Helmut J. F. Salzer1, Rhett J. Stoney2, Kristina M. Angelo2, Thierry Rolling3,4, Martin P. Grobusch5, Michael Libman6, Rogelio López-Vélez7, Alexandre Duvignaud8, Hilmir Ásgeirsson9,10, Clara Crespillo-Andújar11, Eli Schwartz12, Philippe Gautret13, Emmanuel Bottieau14, Sabine Jordan3, Christoph Lange1,15,16, Davidson H. Hamer17,18,*, and GeoSentinel Surveillance Network 1Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Leibniz Lung Center, Borstel, Germany 2Travelers’ Health Branch, Division of Global Migration and Quarantine, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA 3Section of Infectious Diseases and Tropical Medicine, 1st Department of Internal Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany 4Department of Clinical Research, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany 5Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands 6J. D. MacLean Centre for Tropical Diseases, McGill University, Montreal,
    [Show full text]
  • Simultaneous Candida Albicans and Herpes Simplex Virus Type 2
    Reminder of important clinical lesson BMJ Case Rep: first published as 10.1136/bcr-2019-230410 on 15 August 2019. Downloaded from Case report Simultaneous candida albicans and herpes simplex virus type 2 esophagitis in a renal transplant recipient Imran Gani, 1 Vatsalya Kosuru,2 Muhammad Saleem,2 Rajan Kapoor1 1Nephrology, Hypertension and SUMMARY episode of biopsy-proven, borderline, acute cellular Transplant Medicine, Augusta Renal transplant recipients are prone to opportunistic rejection in the second month after transplant that University Health, Augusta, infections due to iatrogenic immunosuppression. responded well to pulse steroids with normalisation Georgia, USA Infectious esophagitis can present as an opportunistic of renal function. 2Internal Medicine, Augusta infection in the post-transplant period. Common Nine months after her kidney transplantation she University Health System, Augusta, Georgia, USA pathogens are candida, herpes simplex virus (HSV) presented with sore throat, dysphagia, odynophagia and cytomegalovirus (CMV). Having a dual infection and fever. Her physical examination was significant Correspondence to is uncommon and the diagnoses can be missed at for oropharyngeal thrush, white tonsillar exudates, Dr Imran Gani, initial presentation. Our patient, a 29-year-old African- pharyngeal erythema and enlarged palatine tonsils. igani@ augusta. edu American woman, status post deceased-donor-kidney Blood work showed leukocytosis and acute kidney transplant presented with difficulty and pain in injury (AKI). She was admitted to the hospital for Accepted 22 July 2019 swallowing with clinical features suggestive of candida intravenous fluids and intravenous fluconazole esophagitis, confirmed by fungal culture. She did not therapy for severe oropharyngeal candidiasis and get better with antifungal treatment. On further testing, high suspicion of esophageal candidiasis.
    [Show full text]